CAR-T Cancer Treatment in China: US Patient’s Story

An American cancer patient traveled more than 11,600 kilometers from Los Angeles to Shenzhen, China, to receive a newly approved CAR-T cell therapy for advanced gastroesophageal cancer.

The case, initially featured in People magazine and subsequently reported by the University of Hong Kong–Shenzhen Hospital, highlights an important development in cancer treatment: China’s approval of the world’s first CAR-T cell therapy for solid tumors.

The patient, Larry Black, received CLDN18.2-targeted CAR-T therapy at the hospital’s International Medical Center. According to the hospital’s October 27, 2026 report, his early treatment results showed substantial tumor regression.

A Journey from Los Angeles to Shenzhen

Larry had been diagnosed with gastroesophageal junction adenocarcinoma, a cancer affecting the area where the esophagus meets the stomach.

Despite undergoing surgery, chemotherapy, immunotherapy, and other treatments, his cancer continued to progress and had spread to the peritoneum, the tissue lining the abdominal cavity.

His wife, Jamie Black, began researching potential treatment options using information from his pathology reports.

One particular biomarker caught her attention: Claudin 18.2 (CLDN18.2).

Her research eventually led the couple to China, where a new CAR-T cell treatment targeting this protein had recently received regulatory approval.

In September 2026, the couple traveled from Los Angeles to Shenzhen to pursue treatment.

China Approves the World’s First CAR-T Therapy for Solid Tumors

On June 22, 2026, China’s National Medical Products Administration (NMPA) approved satricabtagene autoleucel (satri-cel), marketed in China as Kǎilìměi (恺力美).

Developed by CARsgen Therapeutics, the treatment became the world’s first approved CAR-T cell therapy for solid tumors.

Its approved indication in China is for adults with advanced gastric or gastroesophageal junction adenocarcinoma who meet specific criteria:

• Tumors testing positive for CLDN18.2

• HER2-negative disease

• Disease progression or treatment failure following at least two prior lines of systemic therapy

CAR-T therapy has already demonstrated important benefits in certain blood cancers. However, developing effective CAR-T treatments for solid tumors has been considerably more challenging.

The approval represents a significant milestone, although it does not mean the treatment is suitable for every patient with stomach cancer.

How Does CLDN18.2 CAR-T Therapy Work?

CAR-T, or chimeric antigen receptor T-cell therapy, is a form of personalized immunotherapy.

The process involves collecting T cells from the patient’s blood, genetically modifying them to recognize a specific target, multiplying them in a specialized facility, and infusing them back into the patient.

For CLDN18.2-targeted CAR-T therapy, the modified cells are designed to recognize cancer cells expressing the Claudin 18.2 protein.

Unlike conventional chemotherapy, which broadly affects rapidly dividing cells, this approach directs immune cells toward a particular molecular target.

However, CAR-T therapy carries significant medical risks and requires specialized hospital facilities and experienced clinical teams.

Encouraging Early Results in Shenzhen

According to the University of Hong Kong–Shenzhen Hospital, Larry received his CAR-T cell infusion on September 29, 2026.

Following treatment, he experienced fever, swelling of the lower limbs, and a mild decrease in blood pressure. His medical team provided supportive treatment, including tocilizumab, and the reported adverse reactions subsequently improved.

The hospital reported encouraging early findings:

• His CA19-9 tumor marker declined from approximately 8,200 U/mL before infusion to 57.6 U/mL.

• Follow-up imaging showed substantial tumor shrinkage.

• The hospital described his response as approaching complete remission.

• He was subsequently discharged from the hospital.
  

These findings are promising, particularly given his previous disease progression.

Nevertheless, early tumor regression does not establish a cure or guarantee long-term survival. Continued imaging, laboratory monitoring, and clinical follow-up are necessary to determine how durable the response will be.

Could Other International Cancer Patients Receive Similar Treatment in China?

This case demonstrates that certain advanced cancer therapies may become available in China before receiving approval in other countries.

However, suitability for CLDN18.2 CAR-T therapy depends on several medical factors, including:

• The patient’s exact cancer diagnosis and biomarker results

• Previous treatments and responses

• Current disease status and overall physical condition

• Potential complications and the ability to tolerate intensive cell therapy

The treating oncology team must determine whether the patient meets the approved indication and is medically suitable for treatment.

Importantly, not all gastric cancer patients qualify for this therapy, and positive results in one patient do not predict the outcome for another.

Exploring Cancer Treatment Options in China

For international patients considering treatment in China, obtaining an informed specialist opinion can be a useful first step.

China MedCare helps international patients navigate China’s healthcare system and arrange consultations with specialists at public tertiary hospitals.

Our services include:

Medical Second Opinion — USD 99

We can help arrange a second opinion from a Chinese medical specialist to review existing medical information and provide an assessment of potential treatment approaches.

Specialist Appointment Arrangement — USD 29

For patients planning to travel to China, we assist with arranging an initial specialist appointment. Hospital consultation charges, investigations, medications, and treatment costs are paid separately.

China MedCare is an independent medical coordination service, not a hospital or treatment provider. We were not involved in the patient’s treatment described in this article. Access to any specific treatment, including CAR-T therapy, depends on the hospital’s assessment, acceptance, and availability.

We believe patients should carefully consider whether seeking an additional medical opinion is likely to provide meaningful value, particularly when dealing with advanced cancer.

Contact China MedCare to discuss arranging a specialist consultation in China.

⸻

Sources

1. University of Hong Kong–Shenzhen Hospital — Official Patient Case Report, October 27, 2026⁠

2. People Magazine — American Couple Travels to China for CAR-T Treatment, September 22, 2026⁠

3. CARsgen Therapeutics — Regulatory Approval Announcement, June 22, 2026⁠

Medical disclaimer: This article is provided for informational purposes and does not constitute medical advice. Reported results concern an individual patient and should not be interpreted as evidence that other patients will experience similar outcomes.